Biocon Ltd. — Regulatory Filings 2020

Aug 14, 2020

Biocon Limited

20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

August 14, 2020

To	To
The Manager	The Manager,
BSE Limited	National Stock Exchange of India Limited
Department of Corporate Services	Corporate Communication Department
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai – 400 001	Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol - Biocon

Subject: Disclosure pursuant to SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020 ("SEBI Circular") – Impact of Covid-19 pandemic.

Dear Sir/Madam,

Please find enclosed the disclosure on impact of COVID-19 pandemic on our Company as required under SEBI Circular as Annexure A.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

_______________

Mayank Verma Company Secretary and Compliance Officer

Annexure A

S. No.	Particulars	Disclosures
1.A.	Impact of the COVID-19 on	The Covid-19 pandemic has affected business operations across
	the business.	various sectorsof the global economy with restrictions on
		movement of people and goods including lockdowns in India and
		various other countries.
		We operate in the pharmaceutical sector,which the Indian
		government had categorised under essential services. This has
		enabled us to continue the manufacturing and selling of
		pharmaceutical products, with fewer challenges on people
		movement and supply chain.
		As per the current assessment of the situation based on
		internal and external information available todate, we
		believe that the impact of Covid-19 on our business has not
		beensignificant.
2.	Abilitytomaintain	At present, the Company is able to maintain its operations at all
	operationsincludingthe	manufacturing locationsto ensure uninterrupted supply of
	factories/units/officespacesfunctioningand	pharma products.
	closed down.	We have implemented several initiativesacross our facilities
		includingtemperature check during entry, mandatory
		wearing of masks, social distancing at the work place, proper
		and timely sanitization of work places etc.,for ensuring
		safety of our employees and business continuity.
		Employees in manufacturing, quality and R&D continue to report
		at the required strength to our various sites.
		Asprecautionary measure, we have asked a substantial
		number of employees, especially those under support
		functions,suchasFinance,Marketing,HR,ITand
		administration to work remotely from home.
		Adedicatedintranetsiteprovidesemployeeswith
		important information related to Covid-19 guidelines and
		status updates.
3.	Schedule,ifany,forrestarting the operations.	Refer to Point 2 above
4.B.	Stepstakentoensure	The business operations are continuing as mentioned in Point 2
	smoothfunctioningof	above.
	operations.
		Critical levers to support enterprise resilience have been
		identifiedwhichincludefocusonoverallpeoplesafety;
		transparent communication; continuation of critical operations

		such as procurement, production, sales and disposal of waste;compliance and governance; relooking at cash and liquiditymanagement in the changing circumstances and prioritization/rationalization of spends.
		Furthermore, remote working and cyber security, safe plantoperations, impact assessment on R&D andcapex spendsand availability of insurance coverage and contract liabilitieshave been evaluated and key mitigation actions put in placeto support the implementation of business continuity plansand continued safe operations.
5.	Estimation of the futureimpact of COVID-19 on ouroperations.	The business operations are continuing as mentioned in Point 2above
		However, there remain uncertainties associated with the natureand duration on how this pandemic will evolve. The impactassessment of Covid-19 is a continuing process and the Companyis monitoring closely the impact of the same on employee safety,business operations, financial performance, customers, vendorsand business partners.
6.C.	Impact of COVID-19 on:
D.	•Capitalandfinancialresources	None
	•Profitability	Not Material
	•Liquidity position	None
	•Ability to service debtandfinancingarrangements	None
	•Assets	None
	•Internalfinancialreporting and control,	All internal controls and financial reporting systems continue tobe fully operational.
	•Supply chain and	Not Material
	•Demand for its products/services	Not Material
7.A.	Existingcontracts/agreementswherenonfulfilmentoftheobligations by any partywill have significant impactonthelistedentity'sbusiness.	No significant impact of such non- fulfilment of the obligations byany party on our business is expected.
8.B.	Otherrelevantmaterial	None. The Company will provide an update as and when
	updates about the listedentity's business.	there is any material impact on business.